Active — Not RecruitingPhase 2

Reducing Acute Upper Gastrointestinal Side-Effects of Thoracic Irradiation

United States142 participantsStarted 2022-12-13

Plain-language summary

The purpose of the study is to explore options for preventing and reducing symptoms of radiation esophagitis (RE). The researchers will also look what symptoms participants experience, and whether there are differences in weight loss in participants.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients being treated with thoracic irradiation with high-risk esophageal dose as determined below: Esophageal dose: * V50 ≥ 15% (25-35 once daily fractions) or 40 twice-daily \[BID\] fractions) * V40 ≥ 15% (15-24 once daily fractions or 30 twice-daily \[BID\] fractions) * V30 ≥ 15% (10-14 once daily fractions) * Age 18 years of age or older. Exclusion Criteria: * Known inability to take Sucralfate (tablet and/or suspension form), per physician discretion * PEG tube * Actively taking any opioid pain medications prior to radiation therapy * History of an opioid use disorder

What they're measuring

Accrual rate (Two-stage consent part)

Timeframe: 1 year

Reduce opioid use

Timeframe: 2 years

Trial details

NCT IDNCT05659576

SponsorMemorial Sloan Kettering Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12

View on ClinicalTrials.gov More Radiation Esophagitis trials